Dr. Missag Parseghian is a co-founder of Rubicon Biotechnology and is responsible for the protein characterization, assay development and pre-clinical animal studies of Rubicon’s drug candidates. Dr. Parseghian has helped advance the fields of chromatin biology and epigenetics by conducting ground breaking studies on the distribution of linker histone proteins in actively transcribed regions of the cell nucleus and comparing them to regions lacking gene expression, such as the centromeres and telomeres on a chromosome.
Dr. Parseghian is a member of the American Association for Cancer Research and the American Heart Association. He has continued to actively publish and lecture in the areas of antibody engineering and purification; chromosome and chromatin structure; gene regulation; nuclear proteins and their targeting in cancer and cardiovascular therapies.